It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

Pfizer

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Drugmakers pause trials in Russia while still sending medicine

Business Mar 15, 2022

Drugmakers pause trials in Russia while still sending medicine

by Riley Griffin and Robert Langreth

Major pharmaceutical firms are seeking to strike a balance between international opprobrium over Russia’s invasion of Ukraine and the needs of sick patients.

Despite ministry recommendation, some parents in Japan wary of COVID jabs for children

National / Science & Health Feb 16, 2022

Despite ministry recommendation, some parents in Japan wary of COVID jabs for children

by Osamu Tsukimori

Vaccinations for children ages 5 to 11 could start by the end of February, with the government recommending all children receive a shot, particularly those with underlying conditions.

China’s approval of Pfizer pill opens door to ending 'COVID zero'

Asia Pacific Feb 15, 2022

China’s approval of Pfizer pill opens door to ending 'COVID zero'

Having an effective anti-viral in its arsenal could help China mitigate the lower efficacy of its homegrown vaccines if the virus was allowed to circulate more freely.

Japanese health ministry approves Pfizer's COVID-19 oral treatment drug

National / Science & Health Feb 10, 2022

Japanese health ministry approves Pfizer's COVID-19 oral treatment drug

by Osamu Tsukimori

The drug, paxlovid, is to be used for the treatment of mild-to-moderate COVID-19 in people 12 and older and who are at high risk of developing severe symptoms.

Japan's booster rollout is relying on Pfizer and Moderna. How do the shots compare?

National Feb 7, 2022

Japan's booster rollout is relying on Pfizer and Moderna. How do the shots compare?

by Osamu Tsukimori

Despite an apparent preference among some in the general public for Pfizer, experts have emphasized that getting a booster jab as soon as one is eligible, no matter which type, is key.

How does Merck's COVID-19 pill compare to Pfizer's?

World / Science & Health Feb 1, 2022

How does Merck's COVID-19 pill compare to Pfizer's?

by Deena Beasley

Pfizer said final trial results showed that its treatment reduced the chance of hospitalization or death by 89%, while Merck said their pill reduced those chances by 30%.

Pfizer and BioNTech launch trial of omicron-targeted COVID-19 vaccine

World Jan 26, 2022

Pfizer and BioNTech launch trial of omicron-targeted COVID-19 vaccine

The companies plan to test the immune response generated by the omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot.

Japan approves Pfizer shot for children age 5 to 11 as omicron spreads

National Jan 21, 2022

Japan approves Pfizer shot for children age 5 to 11 as omicron spreads

by Osamu Tsukimori

The health ministry has issued fast-track approval to ease the age restriction on receiving the Pfizer vaccine.

The decades of discoveries before the ‘miraculous’ sprint to a vaccine

World / Science & Health Jan 16, 2022

The decades of discoveries before the ‘miraculous’ sprint to a vaccine

by Gina Kolata and Benjamin Mueller

The breakthroughs behind the vaccines unfolded over decades, little by little, as scientists across the world pursued research in disparate areas.

Pfizer seeks approval for oral COVID-19 pill in Japan

National Jan 14, 2022

Pfizer seeks approval for oral COVID-19 pill in Japan

The country has already agreeing to procure enough of the drug, Paxlovid, for 2 million people

Pfizer starts making vaccine that targets both omicron and the original COVID virus

World / Science & Health Jan 11, 2022

Pfizer starts making vaccine that targets both omicron and the original COVID virus

by Riley Griffin

While research continues, Pfizer will evaluate the new hybrid shot against one specific to omicron and determine which should move forward by March, the firm's CEO has said.

The ins and outs of Japan's COVID-19 booster shot rollout

National | EXPLAINER Jan 6, 2022

The ins and outs of Japan's COVID-19 booster shot rollout

by Osamu Tsukimori

Japan recommends people receive a different shot for their third doses to the one they received in the initial rollout, but what's the rationale behind that strategy?

« 1 2 3 … 13 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times